Viking Therapeutics Inc Phase 2 VENTURE Trial of VK2735 Results Call Transcript

Feb 27, 2024 / 01:00PM GMT
Operator

Hello, and welcome to the Viking Therapeutics Phase two venture study Top Line Data Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a Q&A session to ask a question. At that time, please press the star key followed by one on your touchtone phone. Again, that is star one. If anyone has difficulty hearing the conference, please press star zero for OPERATOR assistance. As a reminder, this conference call is being recorded today, February 27th, 2024. And now I would like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Stephanie Diaz - Viking Therapeutics Inc. - Manager-IR

Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO, Marianne Mancini, the Company's Chief Operating Officer, and Greg Zante, Viking's Chief Financial Officer.

Before we begin, I'd like to caution that comments made during this conference call today, February 27, 2024, will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot